U.S. Department of Health & Human Services • National Institutes of Health



National Center for Complementary and Integrative Health

Overview of the NIH Pragmatic Trials Collaboratory and a Cooperative Agreement

Wendy Weber, ND, PhD, MPH Chief, Clinical Research in Complementary and Integrative Health Branch Division of Extramural Research National Center for Complementary and Integrative Health Virtual Onboarding Meeting January 8, 2025



The NIH Collaboratory Story



History: Initiated through the NIH Common Fund in 2012

Selected as the Pragmatic and Implementation Studies for the Management of Pain to Reduce Opioid Prescribing (PRISM) Resource Coordinating Center in 2019




Goal: Strengthen the national capacity to implement costeffective large-scale research studies that engage health care delivery organizations as research partners



Vision: Support the design and execution of innovative pragmatic clinical trial Demonstration Projects to establish best practices and proof of concept



Why Do an ePCT? The 5 Rs





Routinely Collected Data


Can use data collected as part of healthcare delivery to answer the question, supplemented by data from other sources.



Randomized research is needed to answer the question and inform changes in care, policy, or reimbursement.



Program Structure







NIH Collaboratory Trials

- ePCTs addressing questions of major public health importance
- Wide variety of therapeutic areas
- Many have phased funding
 - Planning/Startup phase

Implementation phase





No sites in Arkansas

Lessons Learned

- Expected
 - Missing data
 - Staff turnover
 - Decreased fidelity to intervention
 - Evolving HCS
 - ICD9 to ICD10


Unexpected

- Staff turnover <u>frequency</u>
- Impact of intervention fidelity/adherence
- New EHR launched
- Time effects
 (guidelines)—stepped
 wedge design
- Availability of data at end

Living Textbook of Pragmatic Clinical Trials

- Comprehensive resource for PCTs
- Content organized around Design, Conduct, Dissemination, and Ethics and Regulatory collections
- Authors from Demonstration Projects, Cores, and partners
- Continuously updated







High-Profile Articles



ORIGINAL ARTICLES

Comparison of Approaches for Notification and Authorization in Pragmatic Clinical Research Evaluating Commonly Used Medical Practices

Annals of Internal Medicine[®]

Ideas and Opinions | 7 November 2017

Data Sharing and Embedded Research



A guide to research partnerships for pragmatic clinical trials



The NEW ENGLAND JOURNAL of MEDICINE

Perspective

Is Learning Worth the Trouble? — Improving Health Care System Participation in Embedded Research



Navigating the Murky Waters of Colorectal Cancer Screening and Health Reform

Cooperative Agreements

 \bigcirc

What is a U Mechanism?

- U mechanisms U01, UG3/UH3, and U24 are cooperative agreement awards
 - Used for Investigator-Initiated applications
 - Used by the federal government when the funding agency anticipates federal staff will have involvement in the activities of the award
 - At the time of funding, NIH will assign two staff members to work with investigators:
 - 1. Program Director/Official who is responsible for the administration of the award, review of progress reports, etc.
 - 2. Project Scientist who works directly with the investigators as part of the team and participates in trial planning and oversight

 (\bigcirc)

Benefits of a Cooperative Agreement with a Shared Coordinating Center

- Allows active partnership between NIH and Investigator Team
- More frequent communication
 - Program Scientist is part of your team
 - Tell us what is really going on so we can help
 - Connect you with resources across NIH to resolve challenges and overcome barriers
- Coordinating Center for the Pragmatic Trials Collaboratory
 - Have assisted 28 ePCTs successfully transition and implement
 - Working Groups/Cores set up to address the challenging areas

||(((()))

Additional scientific expertise to help your project

What Is a Phased Award?

- Used when the supported research has two distinct phases (e.g., UG3/UH3) with separate aims
- Transition to the second phase is dependent on whether the first phase achieves the negotiated milestones
 - Examples include test and refine data extraction methods; Institute/Center and DSMB approval of study protocol; finalize all training manuals for sites; active participant in PRISM/HCS Collaboratory activities, etc.

 (\bigcirc)

 If milestones are met, transition to the second phase of funding occurs after administrative review by funding Institute/Center (may get input from trans-NIH PRISM/HCS Collaboratory Implementation Team)

Transition Process

- Pre-Award negotiation of milestones
 - Want them to be objective
 - Easy to evaluate if they have been met Yes or No
- Letter from NIH will describe the process
 - Submit per instructions, 2-3 months prior to transition time (build into timelines)

 (\bigcirc)

- Planning "year" is really 9-10 months
- Document how you have met milestones
- Still need to submit progress report electronically on due date

NIH Review Considerations

- UG3 milestones met
- Potential for meeting UH3 milestones
- Participation in Pragmatic Trials Collaboratory Activities

 (\bigcirc)

- Input from NIH Implementation Team (possible)
- Fit of UH3 milestones and NIH priorities
- Availability of funds